First described by American physician Arthur Janeway in 1899, these lesions are a classic skin manifestation of **infective (bacterial) endocarditis**, especially the sub‑acute form caused by Streptococcus viridans. However, they can also appear in other systemic illnesses that generate circulating emboli or immune complexes.

Common Causes

While infective endocarditis is the leading cause, several other conditions can produce Janeway‑type lesions. Below are the most frequently reported etiologies (arranged alphabetically):

• Acute bacterial endocarditis – especially caused by Staphylococcus aureus or Streptococcus viridans.
• Sub‑acute bacterial endocarditis – often linked to dental procedures or pre‑existing valve disease.
• Autoimmune vasculitis – e.g., microscopic polyangiitis, where small‑vessel inflammation can mimic Janeway lesions.
• Disseminated gonococcal infection – can create painless cutaneous lesions on extremities.
• Embolic phenomena from cardiac tumors – such as atrial myxoma.
• HIV‑related vasculopathy – immune‑complex deposition may produce similar lesions.
• Infective endocarditis secondary to prosthetic heart valves – prosthetic material increases embolic risk.
• Non‑bacterial thrombotic endocarditis (NBTE) – sterile platelet aggregates on valves (often associated with malignancy).
• Septic emboli from infected intravenous lines or catheters.
• Systemic lupus erythematosus (SLE) with vasculitis – rare but reported.

Associated Symptoms

Janeway lesions rarely appear in isolation. They are usually part of a constellation of signs that point toward a systemic process, most commonly infective endocarditis. Commonly co‑existing symptoms include:

• Fever or chills – low‑grade in sub‑acute disease, high‑grade in acute infection.
• Night sweats – especially in chronic infections.
• Fatigue or malaise – a nonspecific but frequent complaint.
• Heart murmur – new or changing murmur suggests valve involvement.
• Other peripheral stigmata of endocarditis:
  • Osler nodes – tender, raised lesions on finger pads.
  • Roth spots – retinal hemorrhages with pale centers.
  • Splinter hemorrhages – linear bleeding under fingernails.
• Arthralgias or migratory joint pain – immune-complex mediated.
• Weight loss – seen in chronic infection or malignancy‑related NBTE.
• Neurologic deficits – stroke or transient ischemic attacks from emboli.

When to See a Doctor

Because Janeway lesions are a red‑flag sign of potentially life‑threatening disease, prompt medical evaluation is essential. Seek care promptly if you notice any of the following:

• Sudden appearance of painless purple spots on palms or soles.
• Fever > 38 °C (100.4 °F) lasting more than 24 hours.
• New or worsening heart murmur.
• Shortness of breath, chest pain, or palpitations.
• Neurologic changes (e.g., weakness, speech difficulty).
• Persistent joint pain or swelling without clear cause.
• Recent dental work, IV drug use, or indwelling catheter placement.

Early evaluation can prevent complications such as heart failure, stroke, or systemic embolization.

Diagnosis

Diagnosing Janeway lesions involves confirming the skin findings and, more importantly, identifying the underlying disease. The diagnostic pathway typically includes:

1. Clinical Examination

• Detailed skin inspection of palms and soles – lesions are non‑tender, flat or slightly raised, and often multiple.
• Cardiovascular exam – listening for murmurs, assessing peripheral perfusion.
• Ophthalmologic exam – looking for Roth spots.
• Joint exam – checking for tenderness or swelling.

2. Laboratory Tests

• Blood cultures – three sets drawn from separate sites before antibiotics; a cornerstone for infective endocarditis diagnosis (CDC/IDSA criteria).
• Complete blood count (CBC) – may reveal anemia or leukocytosis.
• Inflammatory markers – C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are often elevated.
• Serology – for HIV, hepatitis B/C, and syphilis if risk factors are present.
• Autoimmune panel – ANA, anti‑dsDNA, ANCA if vasculitis is suspected.

3. Imaging

• Echocardiography – transthoracic (TTE) first; transesophageal (TEE) if TTE is non‑diagnostic or if prosthetic valves are present.
• CT or MRI of brain – indicated if neurologic symptoms suggest embolic stroke.
• Chest X‑ray – to assess for pulmonary infiltrates or septic emboli.

4. Histopathology (Rare)

In atypical cases, a skin biopsy may be performed. Histology usually shows micro‑abscesses with neutrophilic infiltrate and bacterial colonies in infectious etiologies, whereas non‑infectious causes display fibrinoid necrosis or immune‑complex deposition.

5. Diagnostic Criteria

The Modified Duke Criteria (2015) remain the gold standard for diagnosing infective endocarditis. Janeway lesions count as a “minor criterion.” A combination of major (positive blood cultures, evidence of endocardial involvement on imaging) and minor criteria determines the likelihood of endocarditis.

Treatment Options

Treatment is directed at the underlying cause. The skin lesions themselves usually resolve once the systemic disease is controlled.

1. Infective Endocarditis

• Antibiotic therapy – tailored to the organism identified:
  • Viridans streptococci: Penicillin G or ceftriaxone + gentamicin (if needed).
  • Staphylococcus aureus (MSSA): Nafcillin or oxacillin; MRSA: Vancomycin or daptomycin.
  • Enterococci: Ampicillin + gentamicin or vancomycin + ampicillin.
• Duration: Typically 4–6 weeks of IV therapy, depending on organism and valve status.
• Monitoring: Serial blood cultures, repeat echocardiography, and labs for renal/hepatic function.

2. Surgical Intervention

Indicated when there is:

• Heart failure due to valvular dysfunction.
• Persistent infection despite > 7 days of appropriate antibiotics.
• Large (> 10 mm) mobile vegetations with embolic events.
• Prosthetic valve infection.

3. Management of Non‑Infectious Causes

• Autoimmune vasculitis – high‑dose corticosteroids (e.g., prednisone 1 mg/kg) plus disease‑specific agents (cyclophosphamide, rituximab).
• Disseminated gonococcal infection – ceftriaxone 1 g IV/IM daily plus azithromycin to cover chlamydia.
• NBTE (malignancy‑related) – anticoagulation (heparin bridge to warfarin or direct oral anticoagulant) and treatment of the underlying cancer.
• HIV‑related vasculopathy – antiretroviral therapy (ART) optimization and, if indicated, immunosuppression.

4. Supportive & Home Care

• Maintain good oral hygiene to reduce bacterial load.
• Stay hydrated; adequate fluid intake supports vascular health.
• Avoid picking or scratching lesions to prevent secondary infection.
• Follow up regularly with your cardiologist or infectious disease specialist.

Prevention Tips

Although you cannot prevent all causes, several strategies reduce the risk of developing Janeway lesions by minimizing the underlying conditions:

• Prophylactic antibiotics before dental procedures for patients with high‑risk cardiac conditions (as per AHA guidelines).
• Prompt treatment of skin infections, intravenous drug‑related infections, and catheter‑related sepsis.
• Maintain optimal dental health – regular cleanings and daily brushing/flossing.
• Use aseptic technique for all invasive procedures, including IV line placement.
• Adhere to antiretroviral therapy if HIV‑positive and attend routine monitoring.
• Control chronic diseases (diabetes, hypertension) that predispose to vascular injury.
• Avoid illicit IV drug use; seek addiction treatment if needed.
• For patients with known valvular disease, schedule regular cardiology follow‑ups and echocardiograms.

Emergency Warning Signs

Key Take‑aways

• Janeway lesions are painless, hemorrhagic spots on palms and soles, most often linked to infective endocarditis.
• They are a minor diagnostic criterion but signal serious systemic infection; they should never be ignored.
• Prompt evaluation includes blood cultures, echocardiography, and full infectious work‑up.
• Treatment hinges on targeted antibiotics and, when necessary, cardiac surgery.
• Prevention focuses on oral hygiene, prophylactic antibiotics for high‑risk heart patients, and avoidance of IV drug use.

For personalized advice, always discuss symptoms and treatment options with your health‑care provider. Early recognition saves lives.

References:

1. Mayo Clinic. “Infective endocarditis.” Updated 2023. https://www.mayoclinic.org
2. American Heart Association. “Antibiotic Prophylaxis for Certain Dental Procedures.” 2022. https://www.heart.org
3. CDC. “Infective Endocarditis – Clinical Information.” 2022. https://www.cdc.gov
4. NIH National Institute of Allergy and Infectious Diseases. “Guidelines for the Management of Infective Endocarditis.” 2021.
5. Cleveland Clinic. “Janeway Lesions and Other Peripheral Signs of Endocarditis.” 2023. https://my.clevelandclinic.org
6. World Health Organization. “Antimicrobial resistance and infection control.” 2022.